Seattle-based startup Curi Bio has raised $10 million to advance its platforms for drug discovery, based on human stem cells.
Curi Bio enables screening of new drugs using cells derived from human tissue, called induced pluripotent stem cells (iPSCs). It specializes in cardiac, musculoskeletal, and neuromuscular models. “To discover new therapies requires human-relevant disease models. Curi is working to close the gap between preclinical results and clinical outcomes,” said CEO Michael Cho in a statement on Wednesday announcing the funding.
The startup provides customized research services, including assay development and drug screening for its drug company partners. Curi Bio has partnerships or customer relationships with multiple large biopharma companies.
Curi Bio also sells products for cell culture, including a “Mantarray” platform for growing engineered muscle tissues in three dimensions and measuring their contractility. It also sells a “Cytostretcher” device for experiments involving stretching cells, which can be used to “image live cells during your stretch routines.”
The Series A funding round comes on the heels of a $6 million funding round this spring. The six-year old company also previously has been awarded more than $6 million in grant funding from the U.S. National Institutes of Health.
Last year Curi Bio changed its name from NanoSurface Biomedical and moved into a 5,000-square foot space near Seattle’s waterfront.
In 2020, Curi Bio also acquired Dana Solutions, a startup that applies artificial intelligence and machine learning to cell-based assays. That deal built on a 2019 acquisition of University of Washington spinout and Techstars alum Silene Biotech, a stem cell cryopreservation and banking company.
This October, Curi Bio announced the formation of Seattle-based Celogics, a joint venture company with Korean stem cell company NEXEL. Celogics will focus on developing and commercializing products derived from iPSCs for drug discovery, drug safety testing and research.
As stem cell research has matured over the last few years, numerous companies have formed to develop therapies based on iPSCs. Others, like Belgium-based NCardia, are more focused on using the cells in screening assays and drug development. NCardia raised $60 million this November to advance its iPSC-based platforms for immuno-oncology.
Curi Bio will use the new funds to scale its business and accelerate development of the Mantarray platform and other tissue analysis offerings. The company has 37 employees.
The new funding round was led by previous investor Dynamk Capital, with participation from new investors, including UTC Investment and DA Asset Management.